Oligometastatic Hormone-Sensitive Prostate Cancer. Why Radiotherapy?
- Author(s)
- Barrado Los Arcos, M; Lopez-Campos, F; Valcarcel, ML; Galdeano Rubio, M; Fernandez de Manzanos, IV; Duque-Santana, V; Gomez Aparicio, M; Martin, JZ; Kishan, AU; Achard, V; Siva, S; Counago, F;
- Details
- Publication Year 2023-06,Volume 21,Issue #3,Page e93-e103
- Journal Title
- Clinical Genitourinary Cancer
- Publication Type
- Review
- Abstract
- Androgen deprivation therapy (ADT) has been considered for years the standard initial treatment for patients with metastatic prostate cancer (mPC). Recently published results support the use of taxanes, second-generation antiandrogens or radiotherapy to the primary tumor as part of the treatment in these patients, considering ADT alone as suboptimal. Metastasis-directed therapy (MDT) is used as part of the treatment for oligometastatic patients in different tumor types. In oligometastatic hormone-sensitive prostate cancer the role of MDT is being studied with promising results. In the present review we assess the available evidence for radiotherapy to the primary tumor in newly diagnosed mPC and for MDT in oligometastatic prostate cancer, as well as future directions in this clinical setting.
- Publisher
- Elsevier
- Keywords
- Male; Humans; *Prostatic Neoplasms/drug therapy/radiotherapy/pathology; Androgen Antagonists/therapeutic use; Hormones; Metastasis-directed therapy; Metastatic prostate cancer; Radiotherapy
- Department(s)
- Radiation Oncology
- PubMed ID
- 36456467
- Publisher's Version
- https://doi.org/10.1016/j.clgc.2022.10.015
- Terms of Use/Rights Notice
- Refer to copyright notice on published article.
Creation Date: 2023-09-05 06:53:43
Last Modified: 2024-07-09 05:03:48